STAT3

[Seminars in Immunopathology] The authors summarize current knowledge on how gp130 signaling and STAT3 in tumor cells and cells of the tumor micro-environment drives hepatic tumorigenesis.

[Experimental Biology and Medicine] To develop an enzalutamide-resistant cell model for molecular mechanism investigation of enzalutamide-resistance, researchers continuously treated C4-2B cells with multiplied concentrations of enzalutamide.

[Signal Transduction and Targeted Therapy] Scientists found that exosomal S100 calcium-binding protein A4 (S100A4) could induce expression of osteopontin, along with other tumor metastasis/stemness-related genes.

[Proceedings of the National Academy of Sciences of the United States of America] Genetic silencing of MDA-9/Syntenin or treatment with a pharmacological inhibitor of the PDZ1 domain, PDZ1i, activated the immune system to kill cancer cells.

[JCI Insight] Researchers reported CD109/STAT3 axis as crucial for the maintenance of stemness and tumorigenicity of glioma stem cells and as a mediator of chemoresistance.

[Cytokine] SH3PXD2A-AS1 silence was found to suppress HaCaT cell proliferation and promote HaCaT cell apoptosis significantly. Meanwhile, SH3PXD2A-AS1 silence significantly increased cleaved-caspase-3 protein levels and inhibited S100A7, TNF-α, IL-6, p-STAT3, STAT3, CyclinD1, and survivin protein levels.